A Therapeutic Dilemma of Venous Thromboembolism in the Setting of Odontogenic Brain and Intramedullary Spinal Cord Abscesses: Case Report and Review of Literature
Courtney Venegas1, Kiley Cameron1, Jennifer Shaw1, Subin Mathew1
1University of Nebraska Medical Center
Objective:
To discuss the role of anticoagulation in the management of venous thromboembolism (VTE) in the setting of metastatic brain and spinal abscesses.  
Background:
Brain and spinal cord abscesses are rare and deadly complications of odontogenic infections. The subsequent development of VTE in concurrence with cerebral emboli is rare, and treatment guidelines are poorly defined. 
Design/Methods:
A case report and review of literature on PubMed was performed and summarized. 
Results:

A 34-year-old male presented with altered mental status, fever, seizures and vomiting. Comprehensive imaging revealed multiple cerebral, spinal, mediastinal, and splenic abscesses. Blood cultures were positive for Streptococcus intermedius, and esophageal biopsy showed Neisseria and Rothia species. Further evaluation identified dental abscess as the likely source of infection. He subsequently developed multiple pulmonary emboli (PE) and deep venous thromboses (DVT) despite antibiotics and DVT prophylaxis. He was treated with an Inferior Vena Cava (IVC) filter and low dose heparin. Dental extraction and Video-Assisted Thoracoscopic Surgery (VATS) were also performed for source control. 

Systematic review identified 35 articles with key words “anticoagulation” and “cerebral abscess.”  The data of 27 cases was summarized as follows: 24/27 patients were treated with anticoagulation (15 (63%) with unfractionated heparin, 6 (25%) with low molecular weight heparin, 1 (4%) with dicumerol, and 2 (8%) with an unnamed agent).  2 (7%)  patients were treated with thrombectomy,  1 (4%) with localized catheter directed streptokinase, and 1 (4%) with aspirin. Average time until diagnosis of VTE and treatment with anticoagulation was 3.5 days. 2 (7%) cases were complicated by cerebral hemorrhage and subsequent death, but both were reported in 1969. 

Conclusions:
In our case, source control and low dose to full dose heparin was not associated with hemorrhagic complications and therefore can be considered safe to use with concomitant VTE. Larger scale trials are needed to further guide standardized treatment.   
10.1212/WNL.0000000000201826